News

At this year's BioVaria in Munich at the end of April, there was a session for very early start-up…

A SPARK-BIH funded project on the development of an innovative tumor-specific immunotherapy for the treatment of B-cell lymphomas has successfully been awarded a follow-on BMBF grant for a first-in-human clinical trial.

Two SPARK-BIH funded teams network with investors and the life science industry at the international JPM BIO Partnering Event.

Dr. Angelika Vlachou, Principal at High-Tech Gründerfonds (HTGF), supported 25 translational SPARK project teams with a dedicated hands-on Pitch Training Workshop.

SPARK-BIH and NeuroCure organized a second Design Thinking workshop.

Researchers led by our SPARKee Ulrike Stein of the ECRC and Robert Preißner of Charité report in "Clinical and Translational Medicine" that statins inhibit a gene that promotes cancer cell metastasis.

NeuroCure grants funding extension to the four NeuroCure/SPARK-BIH teams for an additional year.

Our SPARKees Simone Spuler und Verena Schöwel present their startup MyoPax in Frank Thelen's Podcast Startup-DNA.

The Charité Spin-off BODYCLOCK Technologies by Prof. Dr. Achim Kramer developed a diagnostic assay to assess the circadian clock. The project has previously been supported by SPARK-BIH and BIH Digital Health Accelerator.

SPARK Europe has joint forces for education on translational research and technology transfer! For the third time, European SPARK sites will host a joint webinar series during spring 2022.